Vitamin D Megadose: Definition, Efficacy in Bone Metabolism, Risk of Falls and Fractures

This article was published in the following Dove Press journal:
Open Access Rheumatology: Research and Reviews

Jemina Narvaez, Genessis Maldonado, Roberto Guerrero, Osvaldo Daniel Messina, Carlos Rios

1Rheumatology Department, Espíritu Santo University, Guayaquil, Ecuador; 2Rheumatology Department, Hospital Cosme Argerich, Buenos Aires, Argentina

Introduction: Currently, approximately more than one billion people around the world are considered to have deficient levels of vitamin D. International consensus recommends vitamin D supplementation to high-risk patients (advanced age, osteoporosis, liver failure, malabsorption syndromes, etc.) and those with levels below 30 ng/mL. There are several vitamin D formulations and dosages available, including megadoses. At the moment, there is no consensus on the definition of megadoses. The purpose of this review is to define what is a megadose and analyze its effectiveness in bone metabolism, risk of fractures and falls.

Conclusion: The administration of doses higher than 100,000 IU of vitamin D is considered a megadose. It is evident that the use of megadoses increases serum concentrations of vitamin D; however, there has been no evidence of a decrease in the risk of falls, vertebral fractures or changes in bone mineral density.

Keywords: vitamin D, supplementation, falls, bone mineral density

Introduction
Vitamin D is a pleiotropic steroid hormone, mostly formed from the conversion of 7-dihydrocholesterol to pre-vitamin D3 by ultraviolet light in the keratinocytes. Vitamin D3 is then converted into 25-hydroxycholecalciferol (25-OHD3) in the liver by the enzyme 25-hydroxylase and finally in the proximal tubule of the kidney, the enzyme 25-hydroxyvitamin D-1-hydroxylase converts it into its active form, 1,25-dihydroxycholecalciferol.1

In recent years, there has been an increase in the number of publications about vitamin D and bone metabolism.2-5 Vitamin D allows for calcium absorption at the intestinal level (Figure 1), making calcium homeostasis the main function of vitamin D. Nowadays it is considered that approximately more than one billion people around the world are vitamin D insufficient or deficient and that 50–100% of older men and women in the United States and Europe are vitamin D deficient.6 In Latin American countries, which have a high sun exposure index, vitamin D levels are lower. Doses between 800 and 2000 IU and serum levels ≥30ng/mL of vitamin D have been shown to decrease the risk of fracture.7 Wahl et al Mapped the overall vitamin D status based on a systematic review in different countries. It was evident that only 14% of the countries studied had vitamin D levels above 30ng/mL, 37% had levels between 29 and 20 ng/mL and 49% had levels between 19 and 10 ng/mL.8

International consensus recommends vitamin D supplementation to high-risk patients (advanced age, osteoporosis, liver failure, malabsorption syndromes, etc.) and those with levels below 30 ng/mL.9,10 There are several vitamin D formulations...
and dosages available, including megadoses. At the moment, there is no consensus on the definition of megadoses, however, several studies have used doses higher than 100,000 IU weekly/monthly and have classified them as megadoses.\textsuperscript{11–15} The purpose of this review is to define what is a megadose, and analyze its effectiveness in bone metabolism, risk of fractures and falls.

**Search Methodology**

**Search Strategy**

A systematic search for documents was carried out in the following databases: PubMed, EMBASE, and Cochrane Library. Keywords included “vitamin D”, “megadoses”, “high-dose”, “bone mineral density”, “risk of fracture”, “muscle strength” and “falls”. The search strategy included free text and MeSH terms. Additional studies were sought from the reference list of certain primary studies and relevant reviews.

**Study Selection**

A total of 1178 articles were found, of which 40 were selected by peer-review evaluation. Article selection was limited to studies and systematic reviews in humans and adults, in the English and Spanish languages. Articles that reported associations between high doses of vitamin D and falls, risk of fracture, muscle strength, and bone mineral density were selected. Studies with vitamin D formulations other than ergocalciferol were excluded.

The study was approved by the Ethics and Teaching Committee of the Centro de Reumatología y Rehabilitación (CERER) with a registration number: No.002/2020; Folio 01: Book of Acts No.1.

**Vitamin D Supplementation**

Data from studies in several countries show that serum concentrations of 25 (OH) D should be between 25–50ng/mL,\textsuperscript{16–20} which corresponds to a daily vitamin D intake of 800 IU.\textsuperscript{10} Guidelines recommend that patients with osteoporosis should be supplemented with 800 IU (20µg) of vitamin D per day,\textsuperscript{21,22} higher levels such as 2000 IU (50µmg) daily can also be administered in specific cases, but do not represent a majority in osteoporosis treatment guidelines. Vitamin D requirements vary according to the different guidelines. Table 1 describes the recommendations for vitamin D treatment according to the age group, these range from 400 to 2000 IU.

The Endocrinology Society guidelines recommend 6000 IU (150µg) daily for 8 weeks and a maintenance dose of 1500–2000 IU (37.5–50µg) daily to patients with vitamin D deficiency (≤20 ng/mL) and with following conditions: Rickets, osteomalacia, osteoporosis, chronic kidney disease,
Table 1: Vitamin D Therapy Recommendations According to Age Group

<table>
<thead>
<tr>
<th>Institution</th>
<th>Age (Years)</th>
<th>Dosage</th>
<th>Therapeutic Objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Academy of Medicine, 2011 (USA and Canada)</td>
<td>&lt;1</td>
<td>400 IU</td>
<td>20 ng/mL</td>
</tr>
<tr>
<td></td>
<td>1–70</td>
<td>600 IU</td>
<td></td>
</tr>
<tr>
<td>Society of endocrinology, 2011</td>
<td>&lt;1</td>
<td>400–1000 IU</td>
<td>30 ng/mL</td>
</tr>
<tr>
<td></td>
<td>1–18</td>
<td>600–1000 IU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;18</td>
<td>1500–2000 IU</td>
<td></td>
</tr>
<tr>
<td>DACH countries, 2012 (Austria, Germany and Switzerland)</td>
<td>&lt;1</td>
<td>400 IU</td>
<td>20 ng/mL</td>
</tr>
<tr>
<td></td>
<td>&gt;1</td>
<td>800 IU</td>
<td></td>
</tr>
<tr>
<td>Opinion leaders of vitamin D, 2013 (EVIDAS, Central Europe)</td>
<td>0–6 months</td>
<td>400 IU</td>
<td>30 ng/mL</td>
</tr>
<tr>
<td></td>
<td>6–12 months</td>
<td>400–600 IU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1–18 months</td>
<td>600–1000 IU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16–45</td>
<td>1500–2000 IU</td>
<td></td>
</tr>
<tr>
<td>GULF, 2018 (Arab Emirates)</td>
<td>0–6 months</td>
<td>400 IU</td>
<td>30 ng/mL</td>
</tr>
<tr>
<td></td>
<td>6–12 months</td>
<td>400–600 IU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1–18 months</td>
<td>600–1000 IU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19–65</td>
<td>800–2000 IU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;65</td>
<td>1000–2000 IU</td>
<td></td>
</tr>
</tbody>
</table>

liver failure, malabsorption syndromes (cystic fibrosis, inflammatory bowel disease, Crohn’s disease, bariatric surgery, radiation enteritis), hyperparathyroidism, medications (antinepileptic, antiretroviral, antifungal, cholestyramine), African American and Hispanic population, pregnant women, older adults and granuloma-forming diseases (sarcoidosis, tuberculosis, histoplasmosis).

Doses of 400–800 IU daily increase serum levels of vitamin D, reduces PTH levels and as a result decreases bone resorption marker levels.23–25 The first studies of combined oral vitamin D and calcium therapy were conducted by Chapuy et al, who studied the relationship between supplementation and the frequency of hip fracture and other non-vertebral fractures. 800 IU of cholecalciferol was administered with 1.2 g of calcium daily in healthy women with an average age of 84 years for a period of 18 months. They showed that in the group that received vitamin D plus calcium, the hip fracture number decreased by 43% (p = 0.043) and a decrease in the total number of non-vertebral fractures by 32% (p = 0.015) compared to the placebo group.26 Dawson-Hughes et al evaluated the effect of cholecalciferol (700 IU plus 500mg of calcium) on bone metabolism and the incidence of non-vertebral fractures in 389 subjects older than 65 years. This study reported higher fracture rates in the placebo group than in other controlled trials, where about 22% had fractures compared to 12% of other similar studies.27 Yong et al evaluated in a metanalysis serum vitamin D concentrations before and after supplementation at different doses, indicating that supplementation of doses higher than 100,000 IU were not effective in improving vitamin D levels.28

Definition: What’s a Megadose?

Megadoses have been described as the consumption or administration of nutrients in supraphysiological doses that exceed the recommended dietary ration ten or more times. Its use has been reported since before 1980, spreading this practice in large part by the literature and media that support its use; promising effects that vary from prevention and cure of various diseases to stress relief.29 The first recorded supraphysiological dose of vitamin D comes from a study done in Finland in 1992 by Heikinheimo et al who’s goal was to investigate its effects on the risk of fractures in older adults.11 There is currently no consensus regarding the definition of a megadose, however, several studies use the term “megadose” to refer to doses higher than 100,000 IU of vitamin D. Cavalcante et al rated megadoses as the use of 200,000 IU of cholecalciferol in a single administration.30 Tarcin et al used “megadoses” when administering 300,000 IU of cholecalciferol monthly for 3 months, to patients with vitamin D deficiency and evaluated their endothelial function.14 Table 2 describes the studies that used megadoses for the evaluation of different entities.

Other studies such as VITDISH used megadoses of cholecalciferol (100,000 IU) every 3 months to assess the effects on blood pressure, arterial stiffness, cholesterol levels and endothelial function, without obtaining satisfactory results.33 Scragg et al also used megadoses of cholecalciferol (100,000–200,000 IU monthly) for the prevention of cardiovascular events, without finding significant differences with the placebo group, so they did not recommend its use for the reduction of cardiovascular
risk. Trivedi et al used megadoses of cholecalciferol (100,000 IU every 4 months) for the evaluation of the risk of fracture, and demonstrated a decrease in the incidence of fracture by 22%; however, the patients studied were selected from a base of retired doctors from England. Sanders et al evaluated the frequency of fractures and falls in patients that had been administered with megadoses of cholecalciferol (500,000 IU annually), without finding significant data to support their use for the prevention of falls and fractures. The most recent study by The National Heart, Lung, and Blood Institute PETAL Clinical Trials Network showed that the use of 540,000 IU of vitamin D3 in critically ill patients with vitamin D deficiency did not improve the 90-day mortality rate compared to placebo group. Although there is no universal definition of the term megadoses, many studies call the administration of Vitamin D in doses greater than 100,000 IU megadoses.

Vitamin D and Risk of Falls
Falls are related to a lower quality of life, increased mortality and morbidity. According to WHO data, of all years lived with disabilities, falls are the third most common cause. Approximately 30% of people over 65 have at least one fall per year, 15% have more than two annual falls and 5% of all falls result in fractures.

Deficient levels of vitamin D have been shown to have a negative effect on muscle strength, as there is a reduction in type II muscle fibers. Vitamin D receptor promotes the synthesis of rapid type II proteins in the muscle, which are responsible for rapid contraction and balancing activities of short duration and high intensity; resulting in muscle mass being a relevant factor for the prevention of falls. Snijder et al showed an association between serum levels of 25 (OH) D and the risk of falls in older adults. Patients who presented levels <10 ng/mL had a risk of falling two to three times higher in 1 year than those who had normal levels of vitamin D.

Smith et al studied the frequency of falls at different doses of ergocalciferol (400, 800, 1600, 2400, 3200, 4000 and 4800 IU daily) for one year, it was evident that in the groups that received 1600–3200 IU of vitamin D, the frequency of falls was lower compared to the groups that received doses higher than 4000 IU; leaving in evidence that high doses and megadoses increase the risk of falling. In addition, the authors showed that, in the subgroup of patients with previous falls, the rate of falls was 68% in low doses of vitamin D, 27% in medium doses and 100% in high doses.

Sanders et al compared a single annual dose of 500,000 IU orally of cholecalciferol versus placebo in 2256 women over 70 years old with a follow-up period of 3 to 5 years. It was reported that women in the cholecalciferol group had 171 fractures versus 135 fractures in the placebo group (p = 0.047); in addition 837 women in the vitamin D group reported 2893 falls versus 2512 falls of 769 women in the placebo group (p = 0.03).

These studies show that although vitamin D megadoses are effective in increasing serum values of 25 (OH) D, they are not effective in decreasing the risk of fracture. Sanders et al showed that serum vitamin D levels increase considerably after megadoses of cholecalciferol, however, over time these levels drop suddenly and continue to decrease until they reach levels similar to the placebo group.

It has even been controversial to demonstrate its use for the improvement of muscle strength and functionality of healthy or fragile patients. Latham et al in 2003 proposed to determine the efficacy of a single dose of 300,000 IU of ergocalciferol and 10 weeks of quadriceps resistance exercises to reduce falls and improve physical performance in frail older adults. It was found that vitamin D did not alter physical performance measures, even in patients with insufficient serum levels of 25 (OH) D (<20 ng/mL).

Megadoses and Risk of Fractures
Smith et al conducted a study, in which they administered 300,000 IU per year of intramuscular ergocalciferol for 3 years in 9440 women and men over 75 years. In the placebo group, 3.87% men and 7.70% women had incidental fractures compared to 3.14% men and 9.26% women in the vitamin D group. In addition, the researchers found no evidence of a protective effect of vitamin D against fractures or falls; concluding that IM administration of vitamin D does not reduce the risk of non-vertebral fractures.

Lyons et al administered 100,000 IU of oral ergocalciferol every 4 months in 3440 subjects, and showed that supplementation to reduce the incidence of fractures was not sufficient, as 205 fractures were recorded in the intervention group and 218 fractures in the control group with a risk ratio of 0.85.

Heikinheimo et al studied the use of megadoses as fracture prophylaxis in elderly patients. They administered 150,000–300,000 IU of ergocalciferol annually over a 4-year period. In the group that received vitamin D, 16.4% presented fractures and in the control group 21.8% (p = 0.034). However, when the type of fracture was evaluated, the incidence of lower limb fractures in the
<table>
<thead>
<tr>
<th>Studies</th>
<th>Number of Participants</th>
<th>Population</th>
<th>Goals</th>
<th>Vitamin D Status in the Population Prior to Megadoses</th>
<th>Results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heikinheimo, 1992</td>
<td>120</td>
<td>Patients aged 75–84 years living in a residential complex of older adults</td>
<td>Vertebbral fracture prophylaxis</td>
<td>Ergocalciferol 150,000–300,000 IU/annual IM 5 years</td>
<td>Total of fractures: Vitamin D group 54 fractures (16.4%), control group 100 (21.8%) (p = 0.024). Lower risk in fractures 9.1% vs 10.7%, respectively (p = 0.27).</td>
<td>In the women group, the prevalence of fractures was lower.</td>
</tr>
<tr>
<td>Trivedi, 2003</td>
<td>2686</td>
<td>Older adult population mostly doctors 65–85 years old, recruited from a national registry</td>
<td>Insufficient: intervention group 21.42 ng/dL, placebo group 15.40 ng/dL</td>
<td>Cholecalciferol 100,000 IU/4 months orally 5 years</td>
<td>Incidence of fractures and total mortality by cause</td>
<td>The study included more men than women; mostly doctors, which increased bias. The prevalence of fractures was lower in the vitamin D group.</td>
</tr>
<tr>
<td>Smith, 2007</td>
<td>9440</td>
<td>Older adult population ≥75 years</td>
<td>Increased risk of non-vertebral fractures (HR 0.99, CI 95% 0.93–1.05)</td>
<td>Ergocalciferol 300,000 IU/annual orally (single dose, every fall season) 3 years</td>
<td>Vitamin D group: Increased risk of non-vertebral fractures (HR 1.09, CI 95% 0.93–1.28), no effect on falls (HR 0.8, CI 95% 0.93–1.04).</td>
<td>Proper study methodology, correct randomization, calculation of the sample present.</td>
</tr>
<tr>
<td>Tarcau, 2009</td>
<td>23</td>
<td>Young adult population</td>
<td>Increased risk of medium flow dilation (MFD) and endothelial function</td>
<td>Cholecalciferol 300,000 IU/monthly IM 3 months</td>
<td>Positive correlation between medium flow dilation (MFD) and endothelial function (r = 0.45; P = 0.001).</td>
<td>The study compares the endothelial response on supplementation in a population deficient in vitamin D with an average of 75 mg/dL of 25 (OH) D.</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Studies</th>
<th>Population</th>
<th>Number of Participants</th>
<th>Vitamin D Megadoses</th>
<th>Duration</th>
<th>Vitamin D Status in the Population Prior to Megadoses</th>
<th>Goals</th>
<th>Results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanders, 2010&lt;sup&gt;15&lt;/sup&gt;</td>
<td>Women aged ≥70 years with a high risk of fracture</td>
<td>2256</td>
<td>Cholecalciferol 500,000 IU/annual orally (single dose, every fall season)</td>
<td>3–5 years</td>
<td>Insufficient: intervention group 15.28 ng/dl, placebo group 12.97 ng/dl</td>
<td>Risk of falls and fractures</td>
<td>Vitamin D group: Increase in falls (RR 1.15, 95% CI 1.02–1.30) and fractures (RR 1.26 95% CI 1.00–1.59). Increased incidence of falls with serum levels were ≥90 nmol/L. NNH: 18 for falls and 32 for fractures.</td>
<td>Proper study methodology, correct randomization, calculation of the present sample and daily record of falls available.</td>
</tr>
<tr>
<td>Pekkarinen, 2010&lt;sup&gt;11&lt;/sup&gt;</td>
<td>Women 63.3–78.8 years old</td>
<td>40</td>
<td>Cholecalciferol 800 IU daily for 1 year, or 97,333 IU/4 months orally</td>
<td>12 months</td>
<td>Insufficient: daily vitamin D group 15.57 ng/dl, vitamin group every 4 months 16.58 ng/dl</td>
<td>Efficacy of different routes of vitamin D administration based on serum levels</td>
<td>Daily administration group increased its 25 (OH) D more than the 4-month group (P &lt;0.0001). 100% of group D and 67% of the 4M group had levels &gt;50 nmol/L at 12 months, 47% and 28% of each group reached levels &gt;75 nmol/L.</td>
<td>The use of 800 IU daily showed a higher serum concentration in comparison to the megadoses.</td>
</tr>
<tr>
<td>Witham, 2013, ViDISH&lt;sup&gt;13&lt;/sup&gt;</td>
<td>Patients ≥70 years with systolic hypertension</td>
<td>159</td>
<td>Cholecalciferol 100,000 IU/3 months orally</td>
<td>1 year</td>
<td>Insufficient: intervention group and placebo 18 ng/dl</td>
<td>Difference in blood pressure, arterial stiffness, endothelial function, cholesterol levels, insulin resistance and b-natriuretic peptide</td>
<td>Vitamin D group increased an average of 8ng/dl per year (p &lt;0.001). No effect of vitamin D on cardiovascular health.</td>
<td>The difference in the number of falls between the groups was not significant (36 vs 46 p = 0.24).</td>
</tr>
<tr>
<td>Khaw, 2017, VIDA&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Patients aged 50–84, residents of Auckland, recruited from a national registry</td>
<td>5110</td>
<td>Cholecalciferol Initial dose 200,000 IU orally, monthly, followed by 100,000 IU/ monthly</td>
<td>3–4 years</td>
<td>Insufficient: the entire population studied 18.17 ng/dl</td>
<td>Cardiovascular disease, respiratory infections, falls and non-vertebral fractures</td>
<td>Falls: Vitamin D group 52%, control group 53% (HR 0.99 CI 95% 0.92–1.07 p = 0.82); non-vertebral fractures: 156 vs 136, respectively (HR 1.19 CI 95% 0.94–1.50 p = 0.15)</td>
<td>The sample calculation was performed, and they detected that the study has an 80% probability of detecting a risk ratio (HR) of 0.76 for non-vertebral fractures, anticipating that 430 participants were going to present a fracture.</td>
</tr>
</tbody>
</table>
vitamin D group was 9.1% versus 10.7% in the control group (p = 0.27). In contrast, one of the few studies that has shown benefits with the administration of megadoses has been conducted by Trivedi et al. They administered 100,000 IU of oral cholecalciferol every 4 months to 2686 doctors in Great Britain aged 65 years or older. 268 incidental fractures and 147 osteoporotic fractures were recorded. In the group that received vitamin D, the incidence of the first fracture at any site decreased by 22% and the incidence of hip, wrist and forearm fractures was reduced by 33%. There was no significant data on the relative risk of mortality and vitamin D (p = 0.18).

Recently, Reid et al conducted a clinical trial to determine the effect of vitamin D megadoses on bone mineral mass in patients with insufficient levels of 25 (OH) D. A monthly dose of 100,000 IU of cholecalciferol was administered for two years and bone mass controls were performed by densitometry, no significant changes in the lumbar spine were evidenced, concluding that megadoses do not have a positive effect on the increase in bone mineral mass.

**Other High Doses of Vitamin D**

Clinical trials evaluating the efficacy of Vitamin D have been performed in which daily doses of 10,000 IU are administered or at weekly and monthly intervals with doses ranging from 20,000 to 60,000 IU. In 2008, Ish-Shalom et al analyzed the effects of the different dosages of cholecalciferol in three intervention groups: 1500 IU daily, 10,500 IU weekly and 45,000 IU every 28 days, for two months. Although a greater increase in serum vitamin D concentration was observed on the first day after administration of the monthly dose, no significant differences were observed in serum concentrations of 25 (OH) D of the three groups after two months of intervention; concluding that vitamin D supplementation is equally effective with the three administration frequencies evaluated.

In contrast, Singh et al studied two intervention groups in patients with vitamin D deficiency and musculoskeletal symptoms such as myalgia, fatigue, malaise and paresthesia; The first group was administered 60,000 IU weekly of cholecalciferol and the second, 1000 IU daily. The effect of the interventions in reducing symptoms and the increase in serum levels of vitamin D was compared. After 10 weeks of follow-up, the two groups reported symptomatic improvement. However, a greater increase in serum concentrations of 25 (OH) D was observed in the high-dose group with an average difference of 28.33 ng/mL between the groups.

Burt et al evaluated the effect of cholecalciferol supplementation on bone mineral density in patients with adequate levels of vitamin D. They selected three intervention groups for daily administration of vitamin D (400 IU, 4000 IU and 10,000 IU) with a follow-up period of three years. The authors found that patients who received 10,000 IU had greater bone loss compared to those who received 400 IU.

Bischoff-Ferrari et al used monthly high doses of cholecalciferol for the evaluation of functional impairment. They
supplemented women older than 70 years with vitamin D deficiency and functional impairment and defined three groups with the following monthly dosages: 24,000 IU low dose control group, group with a 60,000 IU dose, and a group of 24,000 IU plus 300 µm of calcifediol. They showed that 60,000 and 24,000 IU plus calcifediol increase serum levels, however, they were not effective in improving the function of the lower extremities, and in turn, the risk of falls was higher. It was observed that, paradoxically, adults who reached the highest quartile of vitamin D (44.7–98.9 ng/mL) at 12 months of follow-up were 5.5 times more likely to fall compared to the group that reached the lower quartile below 21.3–30.3 ng/mL of 25 (OH) D (p <0.01).43

Vitamin D Toxicity

Vitamin D toxicity is characterized by hypercalcemia and hypercalciuria, polyuria and seizures.54 The North American Institute of Medicine report classified levels higher than 125nmol/L as toxic and represent potential harm.55 Holick et al defined as excess the levels above 100 ng/mL and intoxication for levels above 150 ng/mL.56 One of the most common causes of vitamin D toxicity is the excessive consumption of fortified products,56 which due to manufacturing errors have been supplemented in excess. A study conducted by Blank et al showed an increase in cases of hypervitaminosis in a population of the United States. 56 cases presented hypervitaminosis and 2 cases were fatal.57 The increasing use of vitamin D treatments has also seen a substantial increase in the number of reports of vitamin D toxicity, due to inappropriate prescription and the use of high-dose over-the-counter preparations or unlicensed preparations.58 On the other hand, the VITAL study showed that supplementation with 2000 IU (50 µg) does not generate adverse effects including hypercalcemia, kidney stones or kidney failure.59

Previously described studies conducted with megadoses and high doses have shown an increase in falls and fractures.15,43,45 This effect is likely to be a consequence of a central nervous toxicity, especially on cerebellar neurons, which contain a high density of vitamin D receptors.60

Discussion

For the purpose of this review, megadoses of vitamin D were defined as the administration of doses greater than 100,000 IU. In addition, fractional doses that exceed 100,000 IU of vitamin D should be considered as megadoses.49,53

Although clinical trials evaluating the effect of vitamin D supplementation on the risk of falls are not uniform, it has been defined that deficient levels of vitamin D are associated with an increased risk of falls and fractures.61–63

In this review, several studies have shown that the use of supraphysiological doses of vitamin D does not denote greater clinical benefits in patients with insufficient serum levels, and which, in turn, could imply an increase in adverse effects, such as the increase in falls and fractures15,43,45: greater loss of bone mass and increased markers of bone resorption.49 compared to those patients who receive adequate supplementation (800–2000 IU), which report a positive effect in reducing the risk of falls and fractures.

The authors propose a vitamin D supplementation algorithm, based on the determination of serum levels of 25 (OH) D, risk factors and comorbidities as a prelude to start supplementing recommended doses according to international guidelines (Figure 2).9,55,64–66 It is important to highlight the individualization of the supplementation for each patient taking into account information such as age, sex, risk factors, history of falls and comorbidities.

Conclusion

Hypovitaminosis D is a widespread problem. The role of vitamin D in bone metabolism and its influence on the risk of falls and fractures is clear. It seems that doses of 800 to 2000 IU daily are effective in maintaining serum levels above 30 ng/mL. The ideal dose for vitamin D supplementation should be individualized according to the serum levels and risk factors of each patient. For years it has been discussed whether the use of high doses of vitamin D, called megadoses, could be effective in maintaining adequate serum levels, reducing the risk of falls and hence fractures. The results of research studies make it clear that megadoses of vitamin D would have an opposite effect from what would be expected of them. The information presented shows that the Megadoses increase the risk of falls, fractures and toxicity, so this form of supplementation would not be the most appropriate. The daily dosage according to the needs of each patient seems to be safer and more effective.

Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.

References


Open Access Rheumatology: Research and Reviews

Publish your work in this journal

Open Access Rheumatology Research and Reviews is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of clinical and experimental rheumatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of rheumatological diseases; Investigation, treatment and management of rheumatological diseases; Clinical trials and novel pharmacological approaches for the treatment of rheumatological disorders. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/open-access-rheumatology-research-and-reviews-journal